Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

58.84USD
2 Oct 2014
Price Change (% chg)

$0.13 (+0.22%)
Prev Close
$58.71
Open
$58.90
Day's High
$58.98
Day's Low
$58.64
Volume
305,039
Avg. Vol
2,571,387
52-wk High
$61.33
52-wk Low
$44.62

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.42
Market Cap (Mil.): $169,356.80
Shares Outstanding (Mil.): 2,884.63
Dividend: 0.44
Yield (%): 3.00

Financials

  MRK.N Industry Sector
P/E (TTM): 30.95 32.97 33.64
EPS (TTM): 1.90 -- --
ROI: 6.92 18.10 17.35
ROE: 11.71 18.80 18.20
Search Stocks

UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study

Oct 1 - An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday.

01 Oct 2014

Esperion drug succeeds in lowering LDL cholesterol -study

Oct 1 - A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

01 Oct 2014

Bayer launches US$7bn six-tranche acquisition bond

NEW YORK, Oct 1 (IFR) - Bayer launched a US$7bn six-tranche acquisition bond financing for Merck's consumer care business Wednesday at levels 10bp-25bp inside of initial price thoughts, leads on the trade said.

01 Oct 2014

BRIEF-Bayer completes takeover of Merck & Co OTC drug unit

* Completes takeover of merck & co otc drug unit Further company coverage:

01 Oct 2014

BRIEF-Bayer closes buy of Merck & Co consumer care business

* Says bayer closes acquisition of consumer care business of merck & co., inc., united states, for usd 14.2 billion

01 Oct 2014

Merck immunotherapy drug shows promise in bladder cancer

MADRID - Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.

29 Sep 2014

Merck immunotherapy drug shows promise in bladder cancer

MADRID, Sept 29 - Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.

29 Sep 2014

Merck drug extends immune system fight to stomach cancer

MADRID - Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

28 Sep 2014

Merck drug extends immune system fight to stomach cancer

* Merck plans to start Phase II study in first quarter 2015

28 Sep 2014

Germany's Merck to buy Sigma-Aldrich for $17 billion to boost lab supplies operation

FRANKFURT - Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.

22 Sep 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks